Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03378739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inova Cardiogenic Shock Registry (INOVA SHOCK)

Study acronym: INOVASHOCK
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Oct 4, 2024, no change to tracked fieldsv7-v9
  2. Enrollment target: 400 to 3000
    • Site contact updated
    v6
  3. Primary and study completion dates: May 29, 2022 to Dec 31, 2099v5
  4. Primary and study completion dates: May 29, 2020 to May 29, 2022
    • Site contact updated
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary and study completion dates: Nov 2018 to May 29, 2020
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2018 to Jan 1, 2018
    • Eligibility criteria revised
    • Secondary endpoints shortened, about 8 words
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017. To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella). • Assess survival at three time points.
Trial Details
NCT Number NCT03378739
Lead Sponsor Inova Health Care Services
Conditions
(from sponsor)		 Cardiogenic Shock
Related terms Shock, Shock, Cardiogenic
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov